Articles by Suzanne Hodsden

31. EMD Serono, Sutro Biopharma Form ADC Partnership 9/18/2014

    EMD Serono, a subsidiary of Merck, and Sutro Biopharma in San Francisco announced a new partnership to collaborate on the production of antibody drug conjugates (ADCs) for undisclosed cancerous targets.

32. Akashi Acquires Global Rights To Tarantula Venom DMD Therapy 9/17/2014

    Akashi announced that it had acquired global rights to GsMTx-4, an amino acid peptide toxin isolated from Grammostola rosea (Chilean rose) tarantula venom, in development with Tonus as a potential therapy for Duchenne Muscular Dystrophy (DMD).

33. Australian Federal Court Upholds Gene Patents 9/10/2014

    The Australian federal court upheld its previous ruling that genetic material removed from the human body could be patented, a move that has many worried for the future of Australian medical research.

34. Catalent, Minomic Collaborate On Prostate Cancer ADC Treatment 9/4/2014

    American company Catalent announced plans to collaborate with Australian Minomic in the manufacturing of a new antibody drug conjugation (ADC), MIL-38, to treat prostate cancer.

35. Researchers: Proteins That Promote HIV/Ebola Virus Also Inhibit Release 8/28/2014

    In an unexpected discovery, scientists at Missouri University have found that proteins that promote the entry of viruses like HIV and Ebola into host cells also possess the ability to block the release of these diseases. Scientists feel this discovery helps to better the understanding of these viruses and could lead to new therapies for stopping their progression.

36. AB SCIEX, Dalton To Develop New ADC Analysis Methods 8/28/2014

    AB SCIEX and Dalton Pharma announced they will collaborate on the development of a new comprehensive method for analyzing Antibody-Drug Conjugates (ADC) with hopes of bringing more biological oncology therapies to market.

37. Insys Therapeutics' Cannabidiol Granted Another Orphan Drug Designation 8/26/2014

    Insys Therapeutics announced that the FDA has granted another orphan drug designation (ODD) for its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), a common and aggressive form of malignant brain tumor. This is the second such designation for Insys’ CBD and the third for cannabis-based pharmaceuticals.

38. Pharming Group Acquires Rare Disease Candidates in TRM SASU Liquidation 8/21/2014

    Dutch biotech company, Pharming Group announced a half million euro deal ($667,000), acquiring assets from the French company, Transgenic Rabbit Models (TRM) SASU, liquidation. This deal gives Pharming Group access to five recombinant human product candidates for the treatment of rare genetic disorders: Pompe’s disease, Fabry’s disease, Gaucher’s disease, and Hemophilia A and B.

39. Glenmark Enters Oncology With Discovery of New Molecule 8/21/2014

    Indian Pharma company, Glenmark has entered oncology with the discovery of GBR 1302, a potential antibody-based therapy for ovarian and breast cancers.

40. CureDuchenne Expands Collaboration With Prosensa 8/13/2014

    CureDuchenne, a U.S. non-profit, announced its plans to expand its long-standing collaboration with biotech Prosensa by $7 million in hopes of accelerating the timelines on four experimental genetic therapies for use in the treatment of Duchenne Muscular Dystrophy (DMD).